Literature DB >> 20042521

Genotypes coding for low serum levels of mannose-binding lectin are underrepresented among individuals suffering from noninfectious systemic inflammatory response syndrome.

Alex Smithson1, Rafael Perello, Jesus Aibar, Gerard Espinosa, Dolors Tassies, Carolina Freire, Pedro Castro, Belen Suarez, Francisco Lozano, Josep-Maria Nicolas.   

Abstract

Gene polymorphisms, giving rise to low serum levels of mannose-binding lectin (MBL) or MBL-associated protease 2 (MASP2), have been associated with an increased risk of infections. The objective of this study was to assess the outcome of intensive care unit (ICU) patients with systemic inflammatory response syndrome (SIRS) regarding the existence of functionally relevant MBL2 and MASP2 gene polymorphisms. The study included 243 ICU patients with SIRS admitted to our hospital, as well as 104 healthy control subjects. MBL2 and MASP2 single nucleotide polymorphisms were genotyped using a sequence-based typing technique. No differences were observed regarding the frequencies of low-MBL genotypes (O/O and XA/O) and MASP2 polymorphisms between patients with SIRS and healthy controls. Interestingly, ICU patients with a noninfectious SIRS had a lower frequency for low-MBL genotypes and a higher frequency for high-MBL genotypes (A/A and A/XA) than either ICU patients with an infectious SIRS or healthy controls. The existence of low- or /high-MBL genotypes or a MASP2 polymorphism had no impact on the mortality rates of the included patients. The presence of high-MBL-producing genotypes in patients with a noninfectious insult is a risk factor for SIRS and ICU admission.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20042521      PMCID: PMC2837953          DOI: 10.1128/CVI.00375-09

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  55 in total

1.  Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition.

Authors:  O Neth; D L Jack; A W Dodds; H Holzel; N J Klein; M W Turner
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study.

Authors:  J P Mira; A Cariou; F Grall; C Delclaux; M R Losser; F Heshmati; C Cheval; M Monchi; J L Teboul; F Riché; G Leleu; L Arbibe; A Mignon; M Delpech; J F Dhainaut
Journal:  JAMA       Date:  1999-08-11       Impact factor: 56.272

Review 3.  The lectin pathway of the complement system.

Authors:  M Matsushita
Journal:  Microbiol Immunol       Date:  1996       Impact factor: 1.955

4.  Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin.

Authors:  P Garred; H O Madsen; U Balslev; B Hofmann; C Pedersen; J Gerstoft; A Svejgaard
Journal:  Lancet       Date:  1997-01-25       Impact factor: 79.321

5.  Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood.

Authors:  A Koch; M Melbye; P Sørensen; P Homøe; H O Madsen; K Mølbak; C H Hansen; L H Andersen; G W Hahn; P Garred
Journal:  JAMA       Date:  2001-03-14       Impact factor: 56.272

6.  Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers.

Authors:  R Steffensen; S Thiel; K Varming; C Jersild; J C Jensenius
Journal:  J Immunol Methods       Date:  2000-07-31       Impact factor: 2.303

7.  Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus.

Authors:  P Garred; H O Madsen; P Halberg; J Petersen; G Kronborg; A Svejgaard; V Andersen; S Jacobsen
Journal:  Arthritis Rheum       Date:  1999-10

8.  Association between deficiency of mannose-binding lectin and severe infections after chemotherapy.

Authors:  N A Peterslund; C Koch; J C Jensenius; S Thiel
Journal:  Lancet       Date:  2001-08-25       Impact factor: 79.321

9.  Mannose-binding lectin-deficient mice display defective apoptotic cell clearance but no autoimmune phenotype.

Authors:  Lynda M Stuart; Kazue Takahashi; Lei Shi; John Savill; R Alan B Ezekowitz
Journal:  J Immunol       Date:  2005-03-15       Impact factor: 5.422

10.  Polymorphisms in CD14, mannose-binding lectin, and Toll-like receptor-2 are associated with increased prevalence of infection in critically ill adults.

Authors:  Ainsley M Sutherland; Keith R Walley; James A Russell
Journal:  Crit Care Med       Date:  2005-03       Impact factor: 7.598

View more
  5 in total

1.  Mannose-Binding Lectin Levels in Critically Ill Children With Severe Infections.

Authors:  Erik C Madsen; Emily R Levy; Kate Madden; Anna A Agan; Ryan M Sullivan; Dionne A Graham; Adrienne G Randolph
Journal:  Pediatr Crit Care Med       Date:  2017-02       Impact factor: 3.624

2.  Activation of the lectin pathway of complement by cardiopulmonary bypass contributes to the development of systemic inflammatory response syndrome after paediatric cardiac surgery.

Authors:  I Pągowska-Klimek; A S Świerzko; M Michalski; E Głowacka; A Szala-Poździej; A Sokołowska; M Moll; W R Krajewski; J Romak; M Cedzyński
Journal:  Clin Exp Immunol       Date:  2016-02-08       Impact factor: 4.330

3.  Mannose-binding lectin polymorphisms and the risk of sepsis: evidence from a meta-analysis.

Authors:  A-Q Zhang; C-L Yue; W Pan; J-W Gao; L Zeng; W Gu; J-X Jiang
Journal:  Epidemiol Infect       Date:  2014-01-07       Impact factor: 4.434

4.  Association between mannose-binding lectin variants, haplotypes and risk of hepatocellular carcinoma: A case-control study.

Authors:  Chenghao Su; Yong Lin; Lin Cai; Qianguo Mao; Jianjun Niu
Journal:  Sci Rep       Date:  2016-08-25       Impact factor: 4.379

5.  Mannose-binding lectin-deficient genotypes as a risk factor of pneumococcal meningitis in infants.

Authors:  Carles Bautista-Rodriguez; Cristian Launes; Iolanda Jordan; Maria Andres; Maria Teresa Arias; Francisco Lozano; Juan Jose Garcia-Garcia; Carmen Muñoz-Almagro
Journal:  PLoS One       Date:  2017-05-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.